Other Names for Retatrutide: LY3437943 Explained

Retatrutide, also known by its development code LY3437943, is an investigational medicine developed by Eli Lilly and Company. It has no approved brand name and holds no marketing authorisation in the UK or elsewhere. In research literature it is sometimes described as a "triple agonist" or "triple incretin", referring to its mechanism of action rather than any official designation. This article explains the other names for retatrutide, its regulatory status, what clinical trials have reported, and how it works, to help readers understand what this medicine is and where it currently stands.

What is retatrutide and what other names does it go by?

Retatrutide is the INN for an investigational medicine by Eli Lilly, also identified by the code LY3437943. It has no approved brand name and is sometimes informally called a "triple agonist" in research literature.

Retatrutide is the international non-proprietary name (INN) for an investigational medicine developed by Eli Lilly and Company, and it is also referred to by its development code LY3437943. It does not yet have an approved brand name in the UK or anywhere else, because it has not received a marketing authorisation from any regulatory authority.^[3][4] In clinical and scientific literature, you may encounter it under the code name LY3437943, and some media reports have informally described it as a "triple agonist" or "triple incretin" in reference to its mechanism of action, though these are descriptive terms rather than official names.

It is important to be aware that retatrutide is sometimes confused with other medicines in the same drug class, such as tirzepatide (Mounjaro) or semaglutide (Wegovy, Ozempic). These are distinct, separately authorised medicines and should not be conflated with retatrutide. If you encounter any product being sold online under the name retatrutide, it is not a licensed medicine and may be a falsified or counterfeit product, which could pose serious risks to health. The MHRA advises the public to be cautious about buying medicines from unregulated online sources; further guidance is available at gov.uk/mhra.

Because retatrutide holds no UK marketing authorisation, it can be administered only within an authorised clinical trial. It cannot be obtained through a pharmacy, GP surgery or private clinic outside of that setting. Anyone considering participation in a clinical trial should discuss this with their own GP or specialist in the first instance.

What is the current regulatory status of retatrutide in the UK?

Retatrutide holds no UK marketing authorisation from the MHRA and cannot be prescribed or supplied outside an authorised clinical trial. NICE has issued no guidance, as this follows only after authorisation.

Retatrutide does not hold a marketing authorisation in the UK, and no date can be given for when or whether one may be granted. In the UK, medicines are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).^[4][5] Until the MHRA grants a marketing authorisation following a full review of safety, quality and efficacy data, retatrutide cannot be advertised, and can be prescribed or supplied only within an authorised clinical trial.

NICE, which assesses medicines for NHS use in England, has not issued any guidance on retatrutide, as this step follows only after a medicine has received a marketing authorisation. Similarly, Integrated Care Boards (ICBs), which make local commissioning decisions, have no basis on which to commission retatrutide at this stage.

For people interested in licensed weight-management treatments that are currently available, a GP is the appropriate first point of contact. Licensed options exist and can be discussed in that setting. It is worth noting that anything described or sold online as retatrutide is not a licensed product and has not been assessed for safety or quality by any regulatory authority. Purchasing such products carries significant health risks, and the MHRA advises the public to be cautious about buying medicines from unregulated online sources.

What have clinical trials reported about retatrutide so far?

A 2023 Phase 2 trial in the New England Journal of Medicine reported body weight reductions versus placebo; Phase 3 programmes TRIUMPH and TRANSCEND have since reported results under review. These findings do not constitute regulatory approval.

Clinical trial findings for retatrutide have been reported from both Phase 2 and Phase 3 programmes. A Phase 2 trial published in the New England Journal of Medicine in 2023 examined retatrutide in adults with obesity over 48 weeks.^[1][2] Participants receiving the highest dose studied in that trial achieved substantial mean reductions in body weight compared with placebo, though the trial was not designed to establish long-term safety or to compare retatrutide with other licensed treatments. The Phase 2 programme also included a separate trial in adults with type 2 diabetes.^[14]

The Phase 3 programme, known as TRIUMPH (for obesity) and TRANSCEND (for type 2 diabetes), has since reported results at scientific congresses and in peer-reviewed publications.^[15][16] These larger, longer trials are designed to provide the more robust evidence on efficacy and safety that regulators require before considering a marketing authorisation application. Results from the TRIUMPH and TRANSCEND programmes are being reviewed by the scientific community, and their findings will form part of any future regulatory submission.

As with all investigational medicines, the findings from trials are reported for the populations studied, under controlled conditions, and over defined time periods. They do not predict what any individual would experience. Adverse effects observed in trials have included gastrointestinal symptoms such as nausea, vomiting and diarrhoea, which are common across this class of medicines.^[1][2] Safety monitoring in trials is conducted under strict protocols, and any suspected side effects within a trial are reported to the trial team in accordance with the study protocol.

People participating in a clinical trial involving retatrutide should be aware of several practical safety points. Clinical trials in this area typically exclude people who are pregnant, breastfeeding or planning a pregnancy during the trial period, and participants are usually expected to use effective contraception throughout. If you are a trial participant and require emergency medical care, it is advisable to carry your trial identification and to inform treating clinicians that you are enrolled in a study, so that they can take this into account.

How does retatrutide work and what class of drug is it?

Retatrutide simultaneously activates GLP-1, GIP and glucagon receptors, making it a triple receptor agonist. This mechanism is pharmacologically distinct from currently authorised medicines such as semaglutide and tirzepatide.

Retatrutide is a triple receptor agonist that simultaneously targets three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from currently authorised medicines in the same broad class. Semaglutide (Wegovy, Ozempic) acts on the GLP-1 receptor alone, while tirzepatide (Mounjaro) acts on both the GLP-1 and GIP receptors.^[17][18] Retatrutide adds glucagon receptor agonism as a third mechanism, which is why it is described in research literature as a triple agonist, though this is a pharmacological description rather than an official classification.

GLP-1 receptor agonism promotes insulin secretion in a glucose-dependent manner, reduces glucagon release, slows gastric emptying and acts on appetite-regulating centres in the brain.^[18][22] GIP receptor agonism is thought to complement these effects on insulin secretion and may also influence fat metabolism.^[18][19] Glucagon receptor agonism is hypothesised, partly on the basis of preclinical evidence, to increase energy expenditure and promote fat breakdown in the liver; whether and to what extent these effects translate to humans is still being investigated in the clinical trial programme.^[21][23]

Because retatrutide is investigational, its full safety and tolerability profile has not yet been established to the standard required for a marketing authorisation. The gastrointestinal adverse effects seen in trials are consistent with the GLP-1 receptor agonist class. Any person who experiences a suspected adverse effect while participating in a clinical trial involving retatrutide should report it to the trial team. Suspected side effects from licensed medicines can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; however, for an investigational medicine used only within a trial, the primary reporting route is the trial team or study sponsor.

Frequently Asked Questions